|  |  |
| --- | --- |
|  | **Cave: notitiae huius paginae nec praescriptiones nec consilia medica sunt.** |

**Tractatio encephalomyeliditis disseminatae** strategias therapeuticas diversas in tractandis comprimit. 

In genere distinguuntur therapiae encephalomyeliditis disseminatae in categorias tres vel quattuor:

1. tractationis crisium morbi,
2. praeventionis relapsuum in temporis cursu,
3. tractationis symptomatum specificorum, et
4. tractationum futurarum in damnis neuronalibus morbi causa restituendis.

Tractio imprimis ad crises praventionem spectat, ut symptomata diplopiae (visionis duplicis), sensus vertiginis, perturbationum ambulandi. Talibus in *exacerbationibus* acutis frequenter glucocorticoida (ut prednisolonum) medicamenta adhibeantur. Gravissimis in casibus etiam plasmapheresis (commutatio plasmatis) pernecesse sit — dialysi similis, sanguis extra corpus liberatur; plasmapheresis nimis anticorporum ex sanguine removit. *Praeventio* ad exacerbationes quoad et magnitudinem et frequentiam reducendas valet. Beta-interferona et quaedam aliae substantiae, quae affecti per iniectionem suorum constanter applicare solent. Insuper, si commendetur, natazilumabum vel mitoxanthronum, quod est chemotherapiae similis, therapiae ordinis secundae vel tertiae notae sunt.

Tractationis multorum sympatomatum specificorum ut perturbationis mictionis (vesicae urinariae) vel ambulandi (membri inferioris medicamenta propria remedia divisa sunt.

Incursus morbi
--------------

Methyloprednisolonum in congressionibus tractandis commendatur.
Symptomata nova, ut visus duplex vel imbecillitas repentina, congressionem progressumve morbi suspicionem quaerant tractationemque medicam. Medicamenta ordine primo sunt glucocorticoida, ut prednisolonum vel methyloprednisolonum, quae intra venam applicari solent, at etiam per os sumi queant. Tractatio per 3—5 dies continuare oportet. Effectus adversi sunt per exemplum infectiones, hypertensio arterialis, retentio aquae (oedema).

Si effectibus careant, applicatio hormontis adrenocorticotropini (receptoria melanocortini stimulantis), denique, ordine secundo, plasmapheresis consideranda sunt. Rarius plasmapheresi cyclophosphamidum additum est. 

Et glucocorticoida et hormon adrenocorticotropinum efficaciter securiusque symptomata novorum reducere queant, quam plasmapheresem.

Medicamenta ad relapsuum praeventionem relata
---------------------------------------------

Praeventionis progressus morbi diversae strategiae medicamenta excogitatae sunt, imprimis interferona, anticorpora monoclonalia, et immunomodulatores.

### Interferona

* Interferonum beta 1a
* Interferonum beta 1b

### Anticorpora monoclonalia

* Alemtuzumab
* Natalizumabum
* Ocrelizumab

### Immunomodulatores

* Cladribinum
* Dimethylofumaratum
* Diroximelum fumaratum
* Fingolimod
* Glatiramerum acetatum
* Mitoxantronum
* Ozanimodum
* Siponimodum
* Teriflunomidum

Notae
-----

1. ↑  Hart F. M. Bainbridge J. (Iun 2016). "Current and emerging treatment of multiple sclerosis". *The American journal of managed care* **6 supplementum**: s159-70
2. ↑  Berkovich R. (Ian 2013). "Treatment of acute relapses in multiple sclerosis". *Neurotheraeutics* **10** (1): 97-105 , doi:10.1007/s13311-012-0160-7
3. ↑  Liu S. Liu X. Chen S. Xiao Y. Zhuang W. (Nov 2017). "Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials". *PLoS One* **12** (11): ee0188644 , doi:10.1371/journal.pone.0188644
4. ↑  Cortese I. Chaudhry V. So Y. T. Cantor F. Cornblath D. R. Rae-GrantA. (Ian 2011). "Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology". *Neurology* **76** (3): 294-300 , doi:10.1212/WNL.0b013e318207b1f6
5. ↑  Costello J. Njue A. Lyall M. Heyes A. Mahler N. Philbin M. Nazareth T. (Iul 2019). "Efficacy, safety, and quality-of-life of treatments for acute relapses of multiple sclerosis: results from a literature review of randomized controlled trials". *Degenerative neurological and neuromuscular disease* **9**: 55-78 , doi:10.2147/DNND.S208815

Nexus interni
-------------

* Systema immunitatis

Nexus externi
-------------

* Pellicula Clinicae Mayio de tractationis encephalomyeliditis disseminatae in genere **(Anglice)**